Member Login

Pfizer-BioNTech COVID-19 Vaccine Risk of Allergic Reactions

This week, the U.S. Food and Drug Administration issued the first emergency use authorization (EUA) for a vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The emergency use authorization allows the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S.

With this release, many ACDS members may begin receiving patient inquiries about the risk of adverse reactions to components in the vaccine. The American College of Allergy, Asthma and Immunology (ACAAI) recently released a statement with recommendations on guidance for physicians and other providers related to risk of an allergic reaction to the vaccination.

Click here to view the full ACAAI news release.

Cookie Notice

This website uses cookies to deliver to you the best experience possible on our website. By continuing to use this site, you are providing us with your consent to ensure you receive such an experience. View our privacy policy to learn more.

OK